References
- Saven A., Piro L. D. 2‐Chlorodeoxyadenosine: A newer purine analogue active in the treatment of indolent lymphoid malignancies. Annals of Internal Medicine 1994; 120: 784–791
- Saven A., Piro L. D., Lemon R. H., Figueroa M. L., Kosty M., Ellison D. J., Beutler E. Complete hematologic remissions in chronic‐phase, Philadelphia‐chromosome‐positive, chronic myelogenous leukemia after 2‐chlorodeoxy‐adenosine. Cancer 1994; 73: 2953–2963
- Santana V. M., Mirro J., Jr., Harwood F. C., Cherrie J., Schell M., Kalwinsky D., Blakley R. L. A phase I clinical trial of 2‐chlorodeoxyadenosine in pediatric patients with acute leukemia. Journal of Clinical Oncology 1991; 9: 416–422
- Santana V. M., Mirro J., Jr., Kearas C., Schell M. J., Crom W., Blakley R. L. 2‐Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. Journal of Clinical Oncology 1992; 10: 364–370
- Saven A., Cheung W. K., Smith I., Moyer M., Johannsen T., Rose E., Gollard R., Kosty M., Miller W. E., Piro L. D. Pharmacokinetic study of oral and bolus intravenous 2‐chlorodeoxyadenosine in patients with malignancy. Journal of Clinical Oncology 1996; 14: 978–983
- Petzer A. L., Bilgeri R., Zilian U., Haun M., Geisen F. H., Pragnell I., Braunsteiner H., Konwalinka G. Inhibitory effect of 2‐chlorodeoxyadenosine on granulocytic, erythroid, and T‐lymphocytic colony growth. Blood 1991; 78: 2583–2587
- Petzer A. L., Bilgen R., Geisen F. H., Zilian U., Haun M., Braunsteiner H., Konwalinka G. (1991) Inhibitory activity of 2‐chlorodeoxyadenosine and antagonization by deoxycytidine. Investigations on Human Normal and Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells (CFU‐GM, BFU‐E and CFU‐E). Second International Symposium on the Molecular Biology of Hematopoiens, Innsbrook, Austria, July, 1992, G. Konwalinka, N. G. Abraham